相关实验视频

Updated: Jun 9, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

协生菌对系统性红斑狼疾病活性的影响:随机临床试验的结果

Zahra Mirfeizi¹, Mahmoud Mahmoudi^2,3, Mohammad Hassan Jokar¹

¹Rheumatology Department, Rheumatic Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Journal of food science

|October 22, 2024

概括

综合生菌补充剂显著降低了系统性红斑狼 (SLE) 患者的胰岛素17A (IL-17A) 水平和疾病活性. 这表明共生菌可能是SLE管理的有益辅助疗法.

科学领域:

免疫学免疫学免疫学
胃肠病学胃肠病学
类风湿病学类风湿病学

背景情况:

系统性红斑狼 (SLE) 是一种复杂的自身免疫性疾病,其特征是炎症.
炎症性细胞因子,如17A (IL-17A),是SLE发病的关键驱动因素.
目前的SLE治疗通常涉及免疫抑制疗法,并可能产生副作用.

研究的目的:

评估协生菌作为SLE的辅助疗法的疗效.
评估协生菌对SLE患者IL-17A水平,疾病活性和炎症标志物的影响.
研究协生菌在调节SLE.炎症过程中的潜力.

主要方法:

进行了一项随机,双盲,安慰剂控制的试验.
50名SLE患者被随机分配,接受标准治疗加上协生菌或仅接受标准治疗两个月.
干预包括一种含有多个Lactobacillus和Bifidobacterium菌株以及果性寡糖的共生配方.

主要成果:

与基线相比,同生物组显示IL-17A的蛋白质和mRNA水平显著降低.
系统性狼红斑血病活动指数2000 (SLEDAI-2K) 的得分在同生菌组显著下降.
在安慰剂组中没有观察到IL-17A水平或疾病活性的显著变化.

结论:

同生菌补充剂显示出作为有效的辅助治疗来管理SLE的潜力.
协生菌可能有助于降低SLE患者的关键炎症标志物和疾病活性.
进一步的研究是有必要的,以充分阐明SLE中协生菌的作用机制.

关键词:

这种细菌是Bifidobacterium.牛乳杆菌 (Lactobacillus) 是一种细菌.一个小小的东西.这就是SLE DAI.介质蛋白-17A 介质蛋白-17A 介质蛋白

更多相关视频

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice

Published on: June 8, 2022

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Analysis of Fecal Microbiota Dynamics in Lupus-Prone Mice Using a Simple, Cost-Effective DNA Isolation Method

Published on: May 2, 2022

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...